Pimentel-Aguilar AB, Rodríguez VRN, Méndez SCL

Language: Spanish
References: 12
Page: 28-35
PDF size: 128.32 Kb.

ABSTRACT

The infection risk by mycobacterium tuberculosis is high for the microbiology laboratory personal. It is possible to handle this bacterium using the proper engineering adjustments, administrative procedures and personal working with the appropriate safety measures to content the organism and to ensure the staff protection to that exposition. The Clinical Microbiology Laboratory of the National Institute of Respiratory Diseases deals with tuberculosis multi-drug resistant. An evaluation of the biosafety norms application in that clinical area showed facilities biosafety deficiencies. The purpose of this work was to propose a modification of the Laboratory, determining the actual biosafety level and, according to it, defining the facilities and equipment characteristics required to create a safe environment for the personal; the qualitative benefits of the modifications are also presented. A cost-utility analysis demonstrated that the project monetary inversion is equivalent to thirteen years of treatment of common tuberculosis infected person, or three years in the case of multi-drug resistant tuberculosis infection.

REFERENCES

1. Biosafety in Microbiological and Biomedical Laboratories, Centers for Disease Control and Prevention and National Institutes of Health, Washington, 1999: pp. 5-56

2. Secretaría de Salud. La tuberculosis causa tres millones de muertes al año en el mundo. Comunicado No. 205, México 2005.

3. Fernández R, De la Cruz F. Riesgo biológico ocupacional y medidas de seguridad en los laboratorios médicos. Disponible en: www.cepis.org.pe/eswww/fulltext/repind61/rbomslm/rboms.html

4. Ostrosky-Zeichner L, Rangel-Frausto MS, García-Romero E, Vázquez A, Ibarra MJ, Ponce De León-Rosales S. Tuberculosis en trabajadores de la salud: importancia de los programas de vigilancia y control”, Salud Pública de México, 2000; 42(1): 48-52.

5. Chedore P, Th’ng C, Nolan DH, Churchwell GM, Sieffert DE, Hale YM, Jamieson F. Method for inactivating and fixing unstained smear preparation of Mycobacterium tuberculosis for improved laboratory safety. Journal of Clinical Microbiology 2002; 40(11): 4077-4080.

6. Centers for Disease Control and Prevention (1997, Abril). Goals for Working Safely with Mycobacterium tuberculosis in Clinical, Public Health, and Research Laboratories. Disponible en: http://www.cdc.gov/od/ohs/tb/tbdoc2.htm

7. Méndez-Salinas CL. Bioseguridad en laboratorios: Adecuación del Laboratorio de Microbiología Clínica para el cumplimiento de estándares de bioseguridad proyecto terminal. Licenciatura en Ingeniería Biomédica, Universidad Iberoamericana A.C., D.F. México, 2005.

8. Laboratory Center for Disease Control, 1996. Laboratory Biosafety Guidelines. 2nd Edition. Disponible en: http://www.phac-aspc.gc.ca/publicat/lbg-ldmbl-96/index.html

9. Universidad Virtual de Barcelona. Maestría en Gestión de Centros y Servicios de Salud 2005, M4: Economía de la Salud, T4: La evaluación económica de la actividad sanitaria. Disponible en http://www.salud.ubvirtual.com/es

10. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2(3): 187-193.

11. INEGI, Estadísticas Sociodemográficas, 2005. Disponible en http://www.inegi.gob.mx/inegi/contenidos/espanol/prensa/Contenidos/capsulas/2005/sociodemograficas/esperanza.asp?c=1582

12. Vargas-Ruiz M, Ríos-Núñez L, Salazar-Lezama MA, Cano-Valle F. Costos de atención de la tuberculosis: Caso del Instituto Nacional de Enfermedades Respiratorias (INER). Rev Inst Nac de Enfer Resp 2003; 16(4): 219-225.